Six years after hitting the market as the first targeted treatment for patients with a rare genetic tumor mutation, Eli Lilly’s Retevmo (selpercatinib) is solidifying its legacy with a new study that has shown “dramatic” outcomes and showcases the importance of RET fusion biomarker testing.
With several broad indications to its name, Retevmo has been targeting tumors with alterations in the rearranged during transfection (RET) gene for years now. However, the early-stage RET-fusion positive non-small cell lung cancer (NSCLC) patient population has yet to see major benefits from this push—until Lilly’s phase 3 Libretto-432.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.